source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-19 01:00:00
| null |
BRUSSELS AND EMERYVILLE, CALIF., JAN. 19, 2022 /PRNEWSWIRE/ -- REGULATED INFORMATION – INSIDE INFORMATION – UCB (EURONEXT: UCB) AND ZOGENIX (NASDAQ: ZGNX) ANNOUNCED TODAY THAT THE COMPANIES HAVE ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH UCB WOULD ACQUIRE ZOGENIX, INC., A GLOBAL BIOPHARMACEUTICAL COMPANY COMMERCIALIZING AND DEVELOPING THERAPIES FOR RARE DISEASES.
|
UCB TO ACQUIRE ZOGENIX
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-21 08:00:00
| null |
EMERYVILLE, CALIF., DEC. 21, 2021 (GLOBE NEWSWIRE) -- ZOGENIX, A GLOBAL BIOPHARMACEUTICAL COMPANY SPECIALIZING IN RARE DISEASE THERAPIES, ANNOUNCED THAT IT HAS SUBMITTED A NEW DRUG APPLICATION (J-NDA) TO THE JAPANESE MINISTRY OF HEALTH, LABOUR & WELFARE (MHLW) FOR THE MARKETING APPROVAL OF FINTEPLA® (FENFLURAMINE) FOR THE TREATMENT OF EPILEPTIC SEIZURES ASSOCIATED WITH DRAVET SYNDROME IN JAPAN. FINTEPLA RECEIVED ORPHAN DRUG DESIGNATION FROM JAPAN'S MINISTRY OF HEALTH, LABOUR & WELFARE (MHLW) IN AUGUST 2021.
|
ZOGENIX SUBMITS NEW DRUG APPLICATION FOR FINTEPLA® (FENFLURAMINE) IN JAPAN FOR THE TREATMENT OF EPILEPTIC SEIZURES ASSOCIATED WITH DRAVET SYNDROME
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-20 08:00:00
| null |
EMERYVILLE, CALIF., DEC. 20, 2021 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING RARE DISEASE THERAPIES, TODAY ANNOUNCED THAT IT HAS SUBMITTED ITS TYPE II VARIATION MARKET AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY (EMA) FOR FINTEPLA® FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS), A HIGHLY TREATMENT-RESISTANT FORM OF CHILDHOOD-ONSET EPILEPSY. IF APPROVED, THE APPLICATION WOULD EXPAND THE USE OF FINTEPLA IN EUROPE BEYOND DRAVET SYNDROME TO INCLUDE LGS.
|
ZOGENIX SUBMITS TYPE II VARIATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY (EMA) TO EXPAND THE USE OF FINTEPLA® (FENFLURAMINE) FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-16 16:05:00
| null |
EMERYVILLE, CALIF., DEC. 16, 2021 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX) TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS GRANTED INDUCEMENT AWARDS TO NINE (9) NEW NON-EXECUTIVE EMPLOYEES. THE AWARDS WERE MADE ON DECEMBER 15, 2021, UNDER ZOGENIX'S 2021 EMPLOYMENT INDUCEMENT EQUITY INCENTIVE AWARD PLAN, WHICH WAS APPROVED BY THE COMPANY'S BOARD OF DIRECTORS UNDER NASDAQ MARKETPLACE RULE 5635(C)(4), FOR GRANTING EQUITY AWARDS TO NEW EMPLOYEES OF ZOGENIX AS AN INDUCEMENT TO JOIN THE COMPANY. THE AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 84,400 SHARES OF ZOGENIX COMMON STOCK AND 17,300 RESTRICTED STOCK UNITS. THE OPTIONS HAVE A TEN YEAR TERM AND AN EXERCISE PRICE EQUAL TO $13.32 THE CLOSING PRICE PER SHARE OF THE COMMON STOCK ON THE GRANT DATE, AND VEST OVER A FOUR-YEAR PERIOD, WITH 25% OF THE OPTIONS VESTING ON THE FIRST ANNIVERSARY OF EACH EMPLOYEE'S RESPECTIVE START DATE AND THE REMAINDER VESTING IN EQUAL MONTHLY INSTALLMENTS OVER THE THREE YEARS THEREAFTER. THE RESTRICTED STOCK UNITS VEST OVER A FOUR-YEAR PERIOD IN FOUR EQUAL ANNUAL INSTALLMENTS BEGINNING ON THE FIRST ANNIVERSARY OF THE VESTING COMMENCEMENT DATE.
|
ZOGENIX REPORTS GRANTING OF INDUCEMENT AWARDS
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-19 08:00:00
| null |
EMERYVILLE, CALIF., OCT. 19, 2021 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX) TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS GRANTED INDUCEMENT AWARDS TO THIRTY-FOUR (34) NEW NON-EXECUTIVE EMPLOYEES. THE AWARDS WERE MADE ON OCTOBER 15, 2021, UNDER ZOGENIX'S 2021 EMPLOYMENT INDUCEMENT EQUITY INCENTIVE AWARD PLAN, WHICH WAS APPROVED BY THE COMPANY'S BOARD OF DIRECTORS UNDER NASDAQ MARKETPLACE RULE 5635(C)(4), FOR GRANTING EQUITY AWARDS TO NEW EMPLOYEES OF ZOGENIX AS AN INDUCEMENT TO JOIN THE COMPANY. THE AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 75,480 SHARES OF ZOGENIX COMMON STOCK AND 37,790 RESTRICTED STOCK UNITS. THE OPTIONS HAVE A TEN YEAR TERM AND AN EXERCISE PRICE EQUAL TO $15.77, THE CLOSING PRICE PER SHARE OF THE COMMON STOCK ON THE GRANT DATE, AND VEST OVER A FOUR-YEAR PERIOD, WITH 25% OF THE OPTIONS VESTING ON THE FIRST ANNIVERSARY OF EACH EMPLOYEE'S RESPECTIVE START DATE AND THE REMAINDER VESTING IN EQUAL MONTHLY INSTALLMENTS OVER THE THREE YEARS THEREAFTER. THE RESTRICTED STOCK UNITS VEST OVER A FOUR-YEAR PERIOD IN FOUR EQUAL ANNUAL INSTALLMENTS BEGINNING ON THE FIRST ANNIVERSARY OF THE VESTING COMMENCEMENT DATE.
|
ZOGENIX REPORTS GRANTING OF INDUCEMENT AWARDS
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-30 08:00:00
| null |
EMERYVILLE, CALIF., SEPT. 30, 2021 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING RARE DISEASE THERAPIES, TODAY ANNOUNCED DATA FROM AN INTERIM ANALYSIS OF AN ON-GOING 12-MONTH PHASE 3 OPEN-LABEL EXTENSION (OLE) STUDY (STUDY 1601; PART 2) SHOWING THAT TREATMENT WITH FINTEPLA® (FENFLURAMINE) ORAL SOLUTION LED TO A CLINICALLY MEANINGFUL AND SUSTAINED REDUCTION IN DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME (LGS) ON ANTISEIZURE MEDICATIONS (ASMS). LGS IS A RARE, SEVERE CHILDHOOD-ONSET FORM OF EPILEPSY IN WHICH SEIZURES ARE EXTREMELY DIFFICULT TO CONTROL AND ARE ASSOCIATED WITH SIGNIFICANT COGNITIVE, BEHAVIORAL, AND MOTOR DISABILITIES. THESE DATA WERE PRESENTED TODAY AT THE CHILD NEUROLOGY SOCIETY (CNS) 2021 ANNUAL MEETING, WHICH IS BEING HELD SEPTEMBER 29 - OCTOBER 2, 2021.
|
NEW FINTEPLA® (FENFLURAMINE) DATA SHOW LONG-TERM SEIZURE FREQUENCY REDUCTIONS IN PATIENTS WITH LENNOX-GASTAUT SYNDROME (LGS)
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-16 17:39:00
| null |
EMERYVILLE, CALIF., SEPT. 16, 2021 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX) TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS GRANTED INDUCEMENT AWARDS TO FOURTEEN (14) NEW EMPLOYEES. THE AWARDS WERE MADE ON SEPTEMBER 15, 2021, UNDER ZOGENIX'S 2021 EMPLOYMENT INDUCEMENT EQUITY INCENTIVE AWARD PLAN, WHICH WAS APPROVED BY THE COMPANY'S BOARD OF DIRECTORS UNDER NASDAQ MARKETPLACE RULE 5635(C)(4), FOR GRANTING EQUITY AWARDS TO NEW EMPLOYEES OF ZOGENIX AS AN INDUCEMENT TO JOIN THE COMPANY. THE AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 45,100 SHARES OF ZOGENIX COMMON STOCK AND 22,600 RESTRICTED STOCK UNITS. THE OPTIONS HAVE A TEN YEAR TERM AND AN EXERCISE PRICE EQUAL TO $14.69, THE CLOSING PRICE PER SHARE OF THE COMMON STOCK ON THE GRANT DATE, AND VEST OVER A FOUR-YEAR PERIOD, WITH 25% OF THE OPTIONS VESTING ON THE FIRST ANNIVERSARY OF EACH EMPLOYEE'S RESPECTIVE START DATE AND THE REMAINDER VESTING IN EQUAL MONTHLY INSTALLMENTS OVER THE THREE YEARS THEREAFTER. THE RESTRICTED STOCK UNITS VEST OVER A FOUR-YEAR PERIOD IN FOUR EQUAL ANNUAL INSTALLMENTS BEGINNING ON THE FIRST ANNIVERSARY OF THE VESTING COMMENCEMENT DATE.
|
ZOGENIX REPORTS GRANTING OF INDUCEMENT AWARDS
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-16 17:02:00
| null |
EMERYVILLE, CALIF., AUG. 16, 2021 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX) TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS GRANTED INDUCEMENT AWARDS TO FOURTEEN NEW EMPLOYEES. THE AWARDS WERE MADE ON AUGUST 15, 2021, UNDER ZOGENIX'S 2021 EMPLOYMENT INDUCEMENT EQUITY INCENTIVE AWARD PLAN, WHICH WAS APPROVED BY THE COMPANY'S BOARD OF DIRECTORS UNDER NASDAQ MARKETPLACE RULE 5635(C)(4), FOR GRANTING EQUITY AWARDS TO NEW EMPLOYEES OF ZOGENIX AS AN INDUCEMENT TO JOIN THE COMPANY. THE AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 34,580 SHARES OF ZOGENIX COMMON STOCK AND 17,340 RESTRICTED STOCK UNITS. THE OPTIONS HAVE A TEN YEAR TERM AND AN EXERCISE PRICE EQUAL TO $13.75, THE CLOSING PRICE PER SHARE OF THE COMMON STOCK ON AUGUST 13, 2021, AND VEST OVER A FOUR-YEAR PERIOD, WITH 25% OF THE OPTIONS VESTING ON THE FIRST ANNIVERSARY OF EACH EMPLOYEE'S RESPECTIVE START DATE AND THE REMAINDER VESTING IN EQUAL MONTHLY INSTALLMENTS OVER THE THREE YEARS THEREAFTER. THE RESTRICTED STOCK UNITS VEST OVER A FOUR-YEAR PERIOD IN FOUR EQUAL ANNUAL INSTALLMENTS BEGINNING ON THE FIRST ANNIVERSARY OF THE VESTING COMMENCEMENT DATE.
|
ZOGENIX REPORTS GRANTING OF INDUCEMENT AWARDS
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-14 16:01:00
| null |
EMERYVILLE, CALIF., JULY 14, 2021 (GLOBE NEWSWIRE) -- ZOGENIX, A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING RARE DISEASE THERAPIES, AND TEN U.S. ADVOCACY GROUPS TODAY ANNOUNCED THE LAUNCH OF VIP SIBLINGS , A NEW WEBSITE AND SUITE OF MATERIALS CREATED TO CELEBRATE AND DEEPEN SUPPORT FOR SIBLINGS OF ADOLESCENTS LIVING WITH RARE AND SEVERE FORMS OF EPILEPSY. THE SPIRIT OF THE MATERIALS IS CAPTURED BY THE SLOGAN “SIBLINGS. SUPPORTED.”
|
VIP SIBLINGS AND WWW.VIPSIBLING.COM, NEW RESOURCES TO SUPPORT BROTHERS & SISTERS OF THOSE LIVING WITH SEVERE, RARE EPILEPSIES, NOW AVAILABLE FROM ZOGENIX AND 10 ADVOCACY GROUPS
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-21 08:00:00
| null |
EMERYVILLE, CALIF., JUNE 21, 2021 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING RARE DISEASE THERAPIES, TODAY ANNOUNCED THAT MEMBERS OF ITS MANAGEMENT TEAM WILL PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES: THE RAYMOND JAMES HUMAN HEALTH INNOVATION CONFERENCE AND SVB LEERINK CNS FORUM.
|
ZOGENIX TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-22 08:01:00
| null |
EMERYVILLE, CALIF., APRIL 22, 2021 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING RARE DISEASE THERAPIES, TODAY ANNOUNCED NEW DATA SHOWING THE POSITIVE IMPACT OF TREATMENT WITH FINTEPLA® (FENFLURAMINE) ORAL SOLUTION ON EVERYDAY EXECUTIVE FUNCTION FOR CHILDREN AND YOUNG ADULTS WITH LENNOX-GASTAUT SYNDROME (LGS). FINTEPLA IS BEING INVESTIGATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LGS, A RARE, SEVERE EPILEPSY THAT IS ONE OF THE MOST CHALLENGING DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES TO MANAGE DUE TO THE HIGH SEIZURE FREQUENCY AND SIGNIFICANT NEURODEVELOPMENTAL IMPAIRMENT PATIENTS EXPERIENCE.
|
ZOGENIX PRESENTS NEW DATA AT VIRTUAL AAN 2021 SHOWING IMPROVED EXECUTIVE FUNCTION IN LENNOX-GASTAUT SYNDROME (LGS) PATIENTS TREATED WITH FINTEPLA® (FENFLURAMINE) ORAL SOLUTION
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-16 08:00:00
| null |
EMERYVILLE, CALIF., APRIL 16, 2021 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING RARE DISEASE THERAPIES, TODAY ANNOUNCED NEW FINDINGS FROM AN INVESTIGATOR-INITIATED STUDY DESIGNED TO ASSESS CAREGIVERS' PERSPECTIVES ON THE LONG-TERM SEIZURE- AND NON-SEIZURE-RELATED BENEFITS OF FINTEPLA® (FENFLURAMINE) ON PATIENTS WITH DRAVET SYNDROME, A RARE, SEVERE EPILEPSY, AND ON THEIR CAREGIVERS AND FAMILIES. DATA FROM THE STUDY IS BEING PRESENTED DURING THE VIRTUAL AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, APRIL 17-22, 2021.
|
ZOGENIX PRESENTS NEW DATA FROM A STUDY HIGHLIGHTING THE IMPACT OF TREATMENT WITH FINTEPLA® (FENFLURAMINE) ORAL SOLUTION ON DRAVET SYNDROME PATIENTS, CAREGIVERS, AND FAMILIES AT VIRTUAL AAN 2021
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-08 08:00:00
| null |
EMERYVILLE, CALIF., APRIL 08, 2021 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING RARE DISEASE THERAPIES, TODAY ANNOUNCED THAT STEPHEN J. FARR, PH.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND MICHAEL SMITH, EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER, AND TREASURER, WILL PARTICIPATE IN A FIRESIDE CHAT ON MONDAY, APRIL 12, 2021, AT THE 20TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE.
|
ZOGENIX TO PARTICIPATE IN THE 20TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-01 03:00:00
| null |
EMERYVILLE, CALIF., FEB. 01, 2021 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING RARE DISEASE THERAPIES, ANNOUNCED TODAY THAT FINTEPLA® (FENFLURAMINE) ORAL SOLUTION IS NOW AVAILABLE IN GERMANY FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME IN PATIENTS AGED TWO YEARS AND OLDER, AS AN ADD-ON THERAPY TO EXISTING ANTI-EPILEPTIC MEDICATIONS. DRAVET SYNDROME IS A RARE, LIFELONG EPILEPSY THAT BEGINS IN INFANCY AND IS MARKED BY SEVERE REFRACTORY SEIZURES, FREQUENT MEDICAL EMERGENCIES, SIGNIFICANT COGNITIVE AND BEHAVIORAL IMPAIRMENTS, AND AN INCREASED RISK OF SUDDEN PREMATURE DEATH (SUDEP).
|
ZOGENIX'S FINTEPLA® (FENFLURAMINE) ORAL SOLUTION NOW AVAILABLE IN GERMANY FOR THE TREATMENT OF SEIZURES IN DRAVET SYNDROME
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-11 08:00:00
| null |
EMERYVILLE, CALIF., JAN. 11, 2021 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING RARE DISEASE THERAPIES, TODAY REPORTED SELECT PRELIMINARY, UNAUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2020. IN ADDITION, THE COMPANY HIGHLIGHTED ITS KEY 2021 CORPORATE OBJECTIVES.
|
ZOGENIX ANNOUNCES PRELIMINARY, UNAUDITED FOURTH QUARTER 2020 NET PRODUCT SALES
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-21 08:00:00
| null |
EMERYVILLE, CALIF., DEC. 21, 2020 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING RARE DISEASE THERAPIES, ANNOUNCED TODAY THAT THE EUROPEAN COMMISSION (EC) HAS GRANTED MARKETING AUTHORIZATION FOR FINTEPLA® (FENFLURAMINE) ORAL SOLUTION FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME AS AN ADD-ON THERAPY TO OTHER ANTI-EPILEPTIC MEDICINES FOR PATIENTS TWO YEARS OF AGE AND OLDER. DRAVET SYNDROME IS A RARE, LIFELONG EPILEPSY THAT BEGINS IN INFANCY AND IS MARKED BY SEVERE REFRACTORY SEIZURES, FREQUENT MEDICAL EMERGENCIES, SIGNIFICANT COGNITIVE AND BEHAVIORAL IMPAIRMENTS, AND AN INCREASED RISK OF SUDDEN PREMATURE DEATH (SUDEP).
|
THE EUROPEAN COMMISSION APPROVES ZOGENIX'S FINTEPLA® (FENFLURAMINE) ORAL SOLUTION FOR THE TREATMENT OF SEIZURES IN DRAVET SYNDROME
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-03 17:42:00
| null |
CAMBRIDGE, MASS. AND EMERYVILLE, CALIF., DEC. 3, 2020 /PRNEWSWIRE/ -- TEVARD BIOSCIENCES, A PRIVATELY-HELD BIOTECHNOLOGY COMPANY PIONEERING TRNA-BASED GENE THERAPIES, AND ZOGENIX (NASDAQ: ZGNX), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING RARE DISEASE THERAPIES,...
|
TEVARD BIOSCIENCES AND ZOGENIX ANNOUNCE COLLABORATION TO ADVANCE NOVEL GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-09 16:01:00
| null |
EMERYVILLE, CALIF. , NOV. 09, 2020 (GLOBE NEWSWIRE) -- ZOGENIX (NASDAQ: ZGNX), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING AND COMMERCIALIZING RARE DISEASE THERAPIES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 AND PROVIDED A CORPORATE UPDATE. THE COMPANY WILL HOST A CONFERENCE CALL TODAY, MONDAY, NOVEMBER 9, AT 4:30 PM EASTERN TIME/1:30 PM PACIFIC TIME.
|
ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-09-22 18:30:00
| null |
ZOGENIX, INC. ANNOUNCES PROPOSED CONVERTIBLE SENIOR NOTES OFFERING.ZOGENIX INC - INTENTION TO OFFER $200 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027.ZOGENIX INC - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND DEVELOPMENT AND COMMERCIALIZATION OF FINTEPLA IN DRAVET SYNDROME.ZOGENIX INC - ALSO INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND DEVELOPMENT OF MT1621 IN TK2 DEFICIENCY.
|
ZOGENIX ANNOUNCES PROPOSED CONVERTIBLE SENIOR NOTES OFFERING
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-09-10 12:30:00
| null |
ZOGENIX ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS THIRD PIVOTAL PHASE 3 CLINICAL TRIAL (STUDY 3) OF FINTEPLA® IN DRAVET SYNDROME.ZOGENIX INC - POSITIVE STUDY WILL SUPPORT JAPANESE NEW DRUG APPLICATION (J-NDA) SUBMISSION, PLANNED FOR 2021.ZOGENIX - RESULTS CORROBORATE STATISTICALLY SIGNIFICANT CONVULSIVE SEIZURE REDUCTIONS SEEN IN EARLIER MULTINATIONAL PHASE 3 STUDIES OF FINTEPLA IN DRAVET SYNDROME.ZOGENIX INC - FINTEPLA AT 0.7 MG/KG/DAY ACHIEVED A 64.8% GREATER REDUCTION IN MEAN MONTHLY CONVULSIVE SEIZURES COMPARED TO PLACEBO.ZOGENIX INC - FINTEPLA AT A LOWER DOSE OF 0.2 MG/KG/DAY ACHIEVED A 49.9% GREATER REDUCTION IN MEAN MONTHLY CONVULSIVE SEIZURES COMPARED TO PLACEBO.ZOGENIX INC - PHASE 3 STUDY (STUDY 3) OF FINTEPLA MET ITS PRIMARY OBJECTIVE.
|
ZOGENIX ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS THIRD PIVOTAL PHASE 3 CLINICAL TRIALOF FINTEPLA IN DRAVET SYNDROME
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-08-05 19:30:00
| null |
ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 REVENUE $1.0 MILLION.Q2 REVENUE ESTIMATE $545,000 -- REFINITIV IBES DATA.QTRLY LOSS PER SHARE $0.96.
|
ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-25 23:30:00
| null |
FDA APPROVES FINTEPLA® (FENFLURAMINE) FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME.COMMERCIAL LAUNCH OF FINTEPLA PLANNED FOR JULY 2020.
|
FDA APPROVES FINTEPLA® TO TREAT SEIZURES ASSOCIATED WITH DRAVET SYNDROME
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-25 22:30:00
| null |
FDA APPROVES NEW THERAPY FOR DRAVET SYNDROME.U.S. FDA - APPROVED FINTEPLA, A SCHEDULE IV CONTROLLED SUBSTANCE, FOR TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME.U.S. FDA - FDA GRANTED APPROVAL OF FINTEPLA TO ZOGENIX,.U.S. FDA - FINTEPLA LABELING INCLUDES BOXED WARNING STATING DRUG IS ASSOCIATED WITH VALVULAR HEART DISEASE & PULMONARY ARTERIAL HYPERTENSION.
|
FDA APPROVES NEW THERAPY FOR DRAVET SYNDROME
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-03-04 02:30:00
| null |
ZOGENIX PRICES PUBLIC OFFERING OF COMMON STOCK.PRICED AN UNDERWRITTEN PUBLIC OFFERING OF 8,520,000 SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $23.50 PER SHARE.
|
ZOGENIX PRICES PUBLIC OFFERING OF COMMON STOCK
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-03-03 21:30:00
| null |
ZOGENIX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ZOGENIX - TO USE NET PROCEEDS FROM OFFERING TO SUPPORT ACTIVITIES RELATED TO POTENTIAL COMMERCIALIZATION OF FINTEPLA, AMONG OTHER THINGS.
|
ZOGENIX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-02-27 11:30:00
| null |
ZOGENIX ANNOUNCES FDA EXTENSION OF REVIEW PERIOD FOR FINTEPLA® IN DRAVET SYNDROME.ZOGENIX INC - NEW PDUFA TARGET ACTION DATE HAS BEEN EXTENDED BY THREE MONTHS TO JUNE 25, 2020. FOR FINTEPLA.ZOGENIX INC - EXTENSION ALLOWS FDA TIME TO REVIEW ADDITIONAL DATA SUBMITTED BY ZOGENIX IN RESPONSE TO A RECENT INFORMATION REQUEST.ZOGENIX INC - REMAIN VERY CONFIDENT IN DATA SUPPORTING OUR NDA SUBMISSION FOR FINTEPLA FOR TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME.ZOGENIX INC - FDA DETERMINED THAT SUBMISSION OF INFORMATION CONSTITUTED A MAJOR AMENDMENT TO NDA FOR FINTEPLA.
|
ZOGENIX ANNOUNCES FDA EXTENSION OF REVIEW PERIOD FOR FINTEPLA IN DRAVET SYNDROME
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-02-06 20:30:00
| null |
ZOGENIX ANNOUNCES POSITIVE TOP-LINE RESULTS FROM GLOBAL PIVOTAL PHASE 3 TRIAL OF FINTEPLA® FOR THE TREATMENT OF LENNOX-GASTAUT SYNDROME.ZOGENIX INC - PRIMARY ENDPOINT ACHIEVED FROM GLOBAL PIVOTAL PHASE 3 TRIAL OF FINTEPLA.ZOGENIX INC - FINTEPLA ALSO DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT ON MULTIPLE SECONDARY ENDPOINTS.ZOGENIX - MEDIAN % FALL IN MONTHLY DROP SEIZURES BETWEEN BASELINE, TREATMENT PERIOD FOR LOWER DOSE OF FINTEPLA DID NOT REACH STATISTICAL SIGNIFICANCE.
|
ZOGENIX ANNOUNCES POSITIVE TOP-LINE RESULTS FROM GLOBAL PIVOTAL PHASE 3 TRIAL OF FINTEPLA
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-02 22:30:00
| null |
ZOGENIX, INC. PRESENTS AT PIPER JAFFRAY 31ST ANNUAL HEALTHCARE CONFERENCE, DEC-05-2019 10:00 AM. VENUE: THE LOTTE NEW YORK PALACE, 455 MADISON AVENUE, NEW YORK, NEW YORK, UNITED STATES.
|
ZOGENIX, INC. PRESENTS AT PIPER JAFFRAY 31ST ANNUAL HEALTHCARE CONFERENCE, DEC-05-2019 10:00 AM
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-02 19:30:00
| null |
ZOGENIX INC - ANNOUNCED JAMA NEUROLOGY HAS PUBLISHED RESULTS OF ZOGENIX'S PHASE 3 STUDY (STUDY 1504) OF INVESTIGATIONAL DRUG, FINTEPLA.ZOGENIX - ADDITION OF FINTEPLA TO STIRIPENTOL-INCLUSIVE REGIMENS PROVIDED 54% GREATER REDUCTION IN PATIENTS' MEAN MONTHLY CONVULSIVE SEIZURE FREQUENCY.ZOGENIX INC - ZOGENIX'S PHASE 3 STUDY MET ITS PRIMARY EFFICACY ENDPOINT AND ALL KEY SECONDARY ENDPOINTS.
|
ZOGENIX INC - ANNOUNCED JAMA NEUROLOGY HAS PUBLISHED RESULTS OF ZOGENIX'S PHASE 3 STUDY (STUDY 1504) OF INVESTIGATIONAL DRUG, FINTEPLA
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-01 22:30:00
| null |
ZOGENIX, INC. ANNOUNCED THAT JAMA NEUROLOGY HAS PUBLISHED THE RESULTS OF ZOGENIX'S PHASE 3 STUDY (STUDY 1504) OF THE INVESTIGATIONAL DRUG, FINTEPLA® (ZX008, FENFLURAMINE ORAL SOLUTION), IN DRAVET SYNDROME PATIENTS WHOSE ANTIEPILEPTIC DRUG TREATMENT REGIMENS INCLUDED STIRIPENTOL BUT WHO WERE STILL EXPERIENCING A HIGH NUMBER OF CONVULSIVE SEIZURES. DRAVET SYNDROME IS A RARE, SEVERE, AND VERY DIFFICULT TO TREAT INFANTILE-ONSET EPILEPSY CHARACTERIZED BY FREQUENT, DISABLING SEIZURES. THE STUDY DEMONSTRATED THAT ADDING FINTEPLA TO THESE PATIENTS' TREATMENT REGIMENS LED TO A SIGNIFICANT AND CLINICALLY MEANINGFUL (> 50%) REDUCTION IN MONTHLY CONVULSIVE SEIZURE FREQUENCY (MCSF). PATIENTS IN THE FINTEPLA ARM ALSO EXPERIENCED LONGER SEIZURE-FREE INTERVALS, WHICH IS IMPORTANT AS MANY WERE PREVIOUSLY EXPERIENCING MULTIPLE SEIZURES PER WEEK. 'STUDY 1504 WAS AN INTERNATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF 87 DRAVET SYNDROME PATIENTS AGE 2-19 TAKING BACKGROUND ANTI-EPILEPTIC DRUG REGIMENS THAT INCLUDED STIRIPENTOL, RANDOMIZED TO PLACEBO (N=44) OR FINTEPLA 0.4 MG/KG/DAY (N=43). THE STUDY WAS CONDUCTED AT 28 CENTERS IN CANADA, FRANCE, GERMANY, THE NETHERLANDS, SPAIN, THE UNITED KINGDOM AND THE UNITED STATES. ELIGIBLE PATIENTS IN THE TRIAL WERE EXPERIENCING SEIZURES THAT WERE POORLY CONTROLLED WITH THEIR CURRENT ANTI-SEIZURE MEDICATIONS CONSISTING OF STIRIPENTOL PLUS CLOBAZAM AND/OR VALPROIC ACID. AFTER A 6-WEEK PERIOD TO ESTABLISH BASELINE SEIZURE FREQUENCY, PATIENTS WERE RANDOMIZED TO RECEIVE FINETPLA STARTING AT A DOSE OF 0.2 MG/KG/DAY, TWICE-DAILY WITH GRADUAL BLINDED TITRATION OVER A 3 WEEK PERIOD TO 0.4 MG/KG/D (MAXIMUM OF 17 MG PER DAY) OVER 3 WEEKS. PATIENTS MAINTAINED THEIR REGIMEN FOR AN ADDITIONAL 12 WEEKS AT A STABLE DOSE, THEN EITHER CONTINUED TREATMENT IN AN OPEN-LABEL EXTENSION STUDY OR DISCONTINUED TREATMENT. THE STUDY MET ITS PRIMARY EFFICACY ENDPOINT AND ALL KEY SECONDARY ENDPOINTS. PATIENTS TREATED WITH FINTEPLA ACHIEVED A 54% GREATER REDUCTION IN MEAN MCSF THAN THOSE RECEIVING THE PLACEBO (95% CI, 35.6%-67.2%; P>50%) REDUCTION IN MCSF VERSUS 5% WITH PLACEBO (P>75% REDUCTION IN MCSF) WAS EXPERIENCED BY 35% OF FINTEPLA-TREATED PATIENTS COMPARED TO 2% WITH PLACEBO (P=0.003). THE MEDIAN LONGEST SEIZURE-FREE INTERVAL WAS 22 DAYS (3.0-105.0) WITH FINTEPLA AND 13 DAYS (1.0-40.0) WITH PLACEBO (P=0.004). IN THE STUDY, FINTEPLA WAS GENERALLY WELL-TOLERATED AND DEMONSTRATED A SAFETY PROFILE CONSISTENT WITH THE FINDINGS OF ZOGENIX'S FIRST PHASE 3 STUDY OF FINTEPLA IN DRAVET SYNDROME, CALLED STUDY 1, AS WELL AS WITH FINDINGS FROM AN ANALYSIS OF THE COMPANY'S ONGOING OPEN-LABEL EXTENSION STUDY (STUDY 1503). THE MOST COMMON ADVERSE EVENTS IN STUDY 1504 WERE DECREASED APPETITE (19 PATIENTS TAKING FENFLURAMINE [44%] VS 5 TAKING PLACEBO [11%]), FATIGUE (11 [26%] VS 2 [5%]), DIARRHEA (10 [23%] VS 3 [7%]), AND PYREXIA (11 [26%] VS 4 [9%]). ACROSS ALL THREE STUDIES, NO PATIENT EXHIBITED CLINICAL OR ECHOCARDIOGRAPHIC EVIDENCE OF VALVULAR HEART DISEASE OR PULMONARY ARTERIAL HYPERTENSION.
|
JAMA NEUROLOGY PUBLISHES PHASE 3 STUDY OF ZOGENIX, INC. INVESTIGATIONAL DRUG FINTEPLA IN DRAVET SYNDROME PATIENTS TAKING STIRIPENTOL-CONTAINING ANTIEPILEPTIC DRUG REGIMENS
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-25 16:30:00
| null |
ZOGENIX ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION AND PRIORITY REVIEW FOR FINTEPLA® FOR THE TREATMENT OF DRAVET SYNDROME.ZOGENIX INC - FINTEPLA PDUFA TARGET ACTION DATE OF MARCH 25, 2020.ZOGENIX INC - FDA ALSO STATED THAT IT IS NOT CURRENTLY PLANNING TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATION FOR FINTEPLA.
|
ZOGENIX ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION AND PRIORITY REVIEW FOR FINTEPLA FOR THE TREATMENT OF DRAVET SYNDROME
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-24 22:30:00
| null |
ZOGENIX, INC. ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED FOR FILING THE COMPANY’S NEW DRUG APPLICATION (NDA) FOR FINTEPLA® (ZX008, FENFLURAMINE ORAL SOLUTION) FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME. THE FDA GRANTED PRIORITY REVIEW FOR THE NDA FOR FINTEPLA, WHICH PROVIDES FOR A SIX-MONTH REVIEW FROM THE DATE OF RECEIPT, AND ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF MARCH 25, 2020. PRIORITY REVIEW IS GRANTED FOR INVESTIGATIONAL THERAPIES THAT, IF APPROVED, MAY OFFER SIGNIFICANT IMPROVEMENTS IN THE TREATMENT, PREVENTION OR DIAGNOSIS OF A SERIOUS CONDITION. IN ITS NDA FILING ACCEPTANCE LETTER, THE FDA ALSO STATED THAT IT IS NOT CURRENTLY PLANNING TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS THE APPLICATION FOR FINTEPLA. THE NDA IS BASED ON DATA FROM TWO POSITIVE PIVOTAL PHASE 3 TRIALS IN DRAVET SYNDROME AND AN INTERIM ANALYSIS FROM AN ONGOING OPEN-LABEL EXTENSION STUDY, WHICH INCLUDED 232 PATIENTS TREATED FOR UP TO 21 MONTHS. ZOGENIX IS ALSO INVESTIGATING FINTEPLA IN LENNOX-GASTAUT SYNDROME, ANOTHER RARE, SEVERE CHILDHOOD-ONSET EPILEPTIC SYNDROME, FOR WHICH A PHASE 3 TRIAL IS ONGOING, WITH TOP-LINE DATA RESULTS ANTICIPATED IN THE FIRST QUARTER OF 2020.
|
ZOGENIX ANNOUNCES FDA ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION AND PRIORITY REVIEW FOR FINTEPLA® FOR THE TREATMENT OF DRAVET SYNDROME
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-14 22:30:00
| null |
ZOGENIX, INC. PRESENTS AT GUGGENHEIM HEALTHCARE TALKS | IDEA FORUM | NEURO/IMMUNOLOGY DAY, NOV-18-2019 02:30 PM. VENUE: ST. REGIS NEW YORK - THE ROOF, NEW YORK, NEW YORK, UNITED STATES. SPEAKERS: MICHAEL P. SMITH, EXECUTIVE VP, CFO, TREASURER & SECRETARY.
|
ZOGENIX, INC. PRESENTS AT GUGGENHEIM HEALTHCARE TALKS | IDEA FORUM | NEURO/IMMUNOLOGY DAY, NOV-18-2019 02:30 PM
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-07 20:30:00
| null |
ZOGENIX PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $6.75.Q3 REVENUE $600,000.Q3 EARNINGS PER SHARE ESTIMATE $-1.02 -- REFINITIV IBES DATA.Q3 REVENUE ESTIMATE $395,000 -- REFINITIV IBES DATA.
|
ZOGENIX REPORTS Q3 LOSS PER SHARE OF $6.75
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-30 22:30:00
| null |
ZOGENIX, INC., Q3 2019 EARNINGS CALL, NOV 07, 2019
|
ZOGENIX, INC., Q3 2019 EARNINGS CALL, NOV 07, 2019
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-25 11:30:00
| null |
ZOGENIX ANNOUNCES NEW POSITIVE DATA FOR ITS INVESTIGATIONAL DRUG FINTEPLA® IN DRAVET SYNDROME.ZOGENIX INC - DATA HAVE SHOWN LONG-TERM, CLINICALLY MEANINGFUL CONVULSIVE SEIZURE REDUCTION.ZOGENIX INC - DATA HAVE SHOWN CLINICALLY MEANINGFUL AND PROFOUND REDUCTION IN HIGH-RISK TONIC-CLONIC SEIZURES IN PHASE 3 STUDY PATIENTS.ZOGENIX INC - ANTICIPATES TOP-LINE DATA FOR FINTEPLA IN LENNOX-GASTAUT SYNDROME IN Q1 OF 2020.ZOGENIX INC - RESULTS DEMONSTRATED THAT INCREASING FINTEPLA DOSE WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN EXECUTIVE CONTROL.ZOGENIX INC - IN ALL STUDIES, FINTEPLA WAS WELL-TOLERATED.ZOGENIX INC - FINTEPLA DEMONSTRATED RAPID AND CLINICALLY MEANINGFUL REDUCTIONS IN CONVULSIVE SEIZURES AT ALL TEST DOSES.
|
ZOGENIX ANNOUNCES NEW POSITIVE DATA FOR INVESTIGATIONAL DRUG FINTEPLA IN DRAVET SYNDROME
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-24 22:30:00
| null |
ZOGENIX, INC. ANNOUNCED POSITIVE NEW DATA FOR ITS INVESTIGATIONAL DRUG, FINTEPLA® (ZX008, FENFLURAMINE), FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME. THE DATA WERE PRESENTED IN FIVE SCIENTIFIC POSTERS, AVAILABLE HERE, AT THE RECENT CHILDHOOD NEUROLOGY SOCIETY (CNS) CONGRESS. THE POSTERS INCLUDE DATA SHOWING LONG-TERM, CLINICALLY MEANINGFUL REDUCTION IN CONVULSIVE SEIZURE FREQUENCY IN YOUNG DRAVET SYNDROME PATIENTS (UNDER 6 YEARS OF AGE) IN AN ONGOING OPEN-LABEL EXTENSION (OLE) STUDY, AS WELL AS DATA FROM A POST-HOC ANALYSIS SHOWING CLINICALLY MEANINGFUL AND PROFOUND REDUCTION IN THE FREQUENCY OF HIGH-RISK TONIC-CLONIC (GRAND-MAL) SEIZURES IN DRAVET SYNDROME PATIENTS TREATED IN TWO PREVIOUSLY COMPLETED PHASE 3 CLINICAL TRIALS. OTHER DATA INCLUDE THE RESULTS OF A PHASE 1 STUDY TO ASSESS THE POTENTIAL DRUG-DRUG INTERACTION OF FENFLURAMINE AND CANNABIDIOL (CBD). ZX008 (FENFLURAMINE HCL ORAL SOLUTION) PROVIDES LONG-TERM, CLINICALLY MEANINGFUL REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN YOUNG (<6 YEARS OLD) DRAVET SYNDROME SUBJECTS: ANALYSIS FROM LONG-TERM OPEN-LABEL STUDY (J. SULLIVAN, R. NABBOUT, K. KNUPP ET AL). THIS ANALYSIS EXPLORED THE SAFETY AND EFFECTIVENESS OF FENFLURAMINE BY AGE GROUP IN ZOGENIX’S ONGOING OLE STUDY OF FINTEPLA (STUDY 1503). A TOTAL OF 42 OF 158 (26.6%) SUBJECTS ENROLLED IN THE OLE TRIAL WERE UNDER 6 YEARS OF AGE. THE MEDIAN BASELINE MONTHLY CONVULSIVE SEIZURE FREQUENCY FOR THIS AGE GROUP PRIOR TO TREATMENT WAS 10.7 SEIZURES PER MONTH (RANGING FROM 4.0 TO 147.3). AT THE TIME OF ANALYSIS, THE MEDIAN DECREASE IN MONTHLY CONVULSIVE SEIZURE FREQUENCY FOR THE UNDER 6 YEARS OF AGE GROUP OVER THE ENTIRE OBSERVATION PERIOD COMPARED TO BASELINE WAS 75.5% (P<0.001). THIS COMPARED TO A MEDIAN DECREASE OF 60.1% (P<0.001) IN THE OLDER, OVER-6 YEARS OF AGE GROUP AND A MEDIAN DECREASE OF 63.6% (P<0.001) IN THE OVERALL STUDY POPULATION (AGED 2-18 YEARS). FENFLURAMINE WAS GENERALLY WELL-TOLERATED AND NO CASE OF VALVULAR HEART DISEASE OR PULMONARY ARTERIAL HYPERTENSION WAS OBSERVED IN ANY PATIENT AT ANY TIME. DRAVET SYNDROME PATIENTS COMMONLY EXPERIENCE GENERALIZED TONIC-CLONIC SEIZURES, WHICH ARE OFTEN TREATMENT RESISTANT AND HAVE BEEN IDENTIFIED AS A MAJOR RISK FACTOR FOR SUDEP. THIS POOLED ANALYSIS OF TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES (STUDY 1 & STUDY 1504) EVALUATED THE IMPACT OF FINTEPLA ON GENERALIZED TONIC-CLONIC (GRAND MAL) SEIZURES, AND FOCAL-TO-BILATERAL TONIC-CLONIC SEIZURES. A TOTAL OF 206 ENROLLED PATIENTS WERE RANDOMIZED TO PLACEBO (N=84), OR TO TREATMENT WITH FINTEPLA 0.7 (N=40), 0.4 (N=43), OR 0.2 (N=39) MG/KG/DAY. THE MEDIAN BASELINE MONTHLY FREQUENCY OF GENERALIZED TONIC-CLONIC SEIZURES RANGED FROM 8.0 TO 12.3 PER MONTH IN THE FOUR DOSE GROUPS, AND DECREASED BY 80%, 64%, AND 48% IN THE FINTEPLA 0.7, 0.4, AND 0.2 MG/KG/DAY GROUPS, RESPECTIVELY, COMPARED TO 10% IN THE PLACEBO GROUP. FOCAL-TO-BILATERAL TONIC-CLONIC SEIZURES WERE EXPERIENCED BY FEWER PATIENTS AND HAD A MEDIAN BASELINE FREQUENCY OF 2.0 TO 4.7 PER MONTH. DURING TREATMENT, MEDIAN PERCENT REDUCTIONS IN FOCAL-TO-BILATERAL TONIC-CLONIC SEIZURE FREQUENCY WERE 97%, 33% AND 69% IN THE FINTEPLA 0.7, 0.4, AND 0.2 MG/KG/DAY GROUPS, RESPECTIVELY, AND 39% IN THE PLACEBO GROUP. FENFLURAMINE WAS GENERALLY WELL-TOLERATED AND NO CASE OF VALVULAR HEART DISEASE OR PULMONARY ARTERIAL HYPERTENSION OCCURRED IN ANY PATIENT. THE MOST COMMON TREATMENT EMERGENT ADVERSE EVENTS OCCURRING IN =10% OF PATIENTS IN ANY TREATMENT GROUP WERE DECREASED APPETITE, LETHARGY, FATIGUE, SOMNOLENCE, AND DIARRHEA.
|
ZOGENIX, INC. ANNOUNCES NEW POSITIVE DATA FOR ITS INVESTIGATIONAL DRUG FINTEPLA® IN DRAVET SYNDROME
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-16 22:30:00
| null |
ZOGENIX, INC. PRESENTS AT STIFEL 2019 HEALTHCARE CONFERENCE, NOV-19-2019 04:45 PM. VENUE: LOTTE NEW YORK PALACE HOTEL, NEW YORK, NEW YORK, UNITED STATES.
|
ZOGENIX, INC. PRESENTS AT STIFEL 2019 HEALTHCARE CONFERENCE, NOV-19-2019 04:45 PM
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-06 22:30:00
| null |
ZOGENIX, INC. AND ITS WHOLLY-OWNED SUBSIDIARY, MODIS THERAPEUTICS, PRESENTED POSITIVE TOP-LINE RESULTS FROM ITS PIVOTAL PHASE 2 RETRO STUDY AT THE RECENT WORLD MUSCLE SOCIETY CONGRESS IN COPENHAGEN. THE DATA FROM RETRO FORM THE BASIS OF ZOGENIX’S ONGOING INVESTIGATIONAL MT1621 PROGRAM AND SUPPORT THE SAFETY AND EFFICACY OF PYRIMIDINE NUCLEOSIDE SUBSTRATE ENHANCEMENT THERAPY (SET) FOR THE TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D), A RARE, DEBILITATING, AND OFTEN FATAL GENETIC DISORDER THAT PRIMARILY AFFECTS INFANTS AND CHILDREN AND FOR WHICH THERE ARE CURRENTLY NO APPROVED THERAPIES.RETRO IS A GLOBAL RETROSPECTIVE STUDY OF SET, A FIXED COMBINATION TREATMENT OF TWO PYRIMIDINE NUCLEOSIDES (DC/DT), IN 38 PEDIATRIC AND ADULT PATIENTS WITH TK2 DEFICIENCY (MEDIAN AGE OF DISEASE ONSET, 2.5 YEARS) TREATED AT EIGHT CLINICAL SITES IN THREE COUNTRIES (U.S., SPAIN AND ISRAEL). SUBJECTS RECEIVED SET FOR A MEDIAN OF 77 WEEKS (RANGE 92 DAYS – 7 YEARS). EACH SUBJECT WAS SCORED ACROSS MOTOR, RESPIRATORY, AND FEEDING DOMAINS ACCORDING TO PRE-DEFINED RESPONSE CRITERIA AND WAS COMPARED TO PRE-TREATMENT STATUS TO ASSESS WHETHER RESPONSES IMPROVED, REMAINED STABLE, OR WORSENED. PARALLEL TO RETRO, THE COMPANY COMPILED A COMPREHENSIVE, GLOBAL TK2D NATURAL HISTORY DATASET FROM PUBLISHED STUDIES AND INDIVIDUAL CASE REPORTS TO DOCUMENT UNTREATED PATIENTS’ DISEASE COURSE. FROM THIS NATURAL HISTORY DATASET, 68 PATIENTS REFLECTING THE RANGE OF DISEASE SEVERITY, AGE, AND AGE OF DISEASE ONSET, WERE SELECTED AS A CONTROL GROUP FOR TREATED PATIENTS IN THE RETRO STUDY. SAFETY DATA FROM RETRO INDICATED THAT SET IS GENERALLY SAFE AND WELL-TOLERATED. MOST REPORTED ADVERSE EVENTS WERE CONSIDERED NOT RELATED TO STUDY DRUG (199 OF 292), WITH MILD OR MODERATE DIARRHEA BEING THE MOST COMMON TREATMENT-RELATED ADVERSE EVENT, OCCURRING IN 63% OF PATIENTS. SERIOUS AES (SAES) WERE REPORTED IN 14 SUBJECTS (37%). THE MAJORITY OF SAES WERE DEEMED RELATED TO TK2D; TWO PATIENTS EXPERIENCED THREE EVENTS RELATED TO STUDY DRUG ALONE (KIDNEY STONE, KIDNEY STONE REMOVAL, DIARRHEA). TWO ADULT-ONSET PATIENTS STOPPED TREATMENT DUE TO ASYMPTOMATIC INCREASES IN AMINOTRANSFERASE LIVER ENZYMES (NO INCREASE IN BILIRUBIN LEVELS), WHICH RESOLVED UPON DISCONTINUATION OF TREATMENT. MT1621 IS A PROPRIETARY INVESTIGATIONAL DEOXYNUCLEOSIDE SUBSTRATE ENHANCEMENT THERAPY IN LATE-STAGE DEVELOPMENT FOR THE TREATMENT OF TK2 DEFICIENCY (TK2D), A GENETIC DISORDER THAT RESULTS IN MITOCHONDRIAL DYSFUNCTION AND LEADS TO INADEQUATE ENERGY PRODUCTION IN CELLS. TK2D PRESENTS AS SEVERE AND PROGRESSIVE MUSCLE WEAKNESS THAT PROFOUNDLY IMPAIRS MOVEMENT, BREATHING, EATING, AND OTHER NORMAL FUNCTIONS, AND IS OFTEN FATAL. THERE ARE CURRENTLY NO APPROVED THERAPIES FOR THIS DISEASE. DEOXYNUCLEOSIDE COMBINATION THERAPY HAS BEEN SHOWN TO IMPROVE MITOCHONDRIAL FUNCTIONS AND PROLONG SURVIVAL IN PRECLINICAL MODELS, AND DATA FROM INITIAL CLINICAL STUDIES SUGGEST IT MAY MEANINGFULLY ALTER THE COURSE OF DISEASE IN PATIENTS WITH TK2D.
|
ZOGENIX ANNOUNCES POSITIVE CLINICAL STUDY RESULTS FOR INVESTIGATIONAL TREATMENT FOR TK2 DEFICIENCY
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-09-26 09:30:00
| null |
ZOGENIX RESUBMITS NEW DRUG APPLICATION FOR FINTEPLA® FOR THE TREATMENT OF DRAVET SYNDROME TO U.S. FOOD AND DRUG ADMINISTRATION.ZOGENIX - ALSO INVESTIGATING FINTEPLA IN LENNOX-GASTAUT SYNDROME FOR WHICH PHASE 3 TRIAL IS ONGOING AND TOP-LINE DATA ARE ANTICIPATED IN Q1 2020.
|
ZOGENIX RESUBMITS NEW DRUG APPLICATION FOR FINTEPLA FOR TREATMENT OF DRAVET SYNDROME TO U.S. FOOD AND DRUG ADMINISTRATION
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-09-25 22:30:00
| null |
ZOGENIX, INC. ANNOUNCED THAT IT HAS RESUBMITTED ITS NEW DRUG APPLICATION FOR FINTEPLA (ZX008, FENFLURAMINE) FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME TO THE U.S. FOOD AND DRUG ADMINISTRATION. THE NDA IS BASED ON DATA FROM TWO PIVOTAL PHASE 3 TRIALS IN DRAVET SYNDROME AND AN INTERIM ANALYSIS FROM AN ONGOING OPEN-LABEL EXTENSION STUDY, WHICH INCLUDED 232 PATIENTS TREATED FOR UP TO 24 MONTHS. ZOGENIX IS ALSO INVESTIGATING FINTEPLA IN LENNOX-GASTAUT SYNDROME, ANOTHER RARE CHILDHOOD-ONSET EPILEPSY, FOR WHICH A PHASE 3 TRIAL IS ONGOING AND TOP-LINE DATA ARE ANTICIPATED IN THE FIRST QUARTER OF 2020.
|
ZOGENIX RESUBMITS NEW DRUG APPLICATION FOR FINTEPLA FOR THE TREATMENT OF DRAVET SYNDROME TO U.S. FOOD AND DRUG ADMINISTRATION
|
ZGNX
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-26 10:14:00
| null |
BOCA RATON, FLA.--(BUSINESS WIRE)---- $ZGSI #BAMFX--ZGSI ANNOUNCES PUBLICATION OF AN IMPORTANT RESEARCH PAPER VALIDATING ITS TECHNOLOGY IN THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY RESEARCH AND REVIEW
|
ZERO GRAVITY SOLUTIONS, INC.'S ANNOUNCES THE PUBLICATION OF AN IMPORTANT RESEARCH PAPER IN THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY RESEARCH AND REVIEW
|
ZGSI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-25 16:05:00
| null |
NEW YORK, NY / ACCESSWIRE / OCTOBER 25, 2021 / YUNHONG INTERNATIONAL (NASDAQ:ZGYH) (THE "COMPANY") TODAY ANNOUNCED THAT IT HAS RECEIVED A NOTICE ("NOTICE") FROM THE LISTING QUALIFICATIONS DEPARTMENT OF THE NASDAQ STOCK MARKET ("NASDAQ") AS A RESULT OF ITS FAILURE TO FILE ITS ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED JUNE 30, 2021 (THE "FORM 10-K") IN A TIMELY FASHION. THE NOTICE ADVISED THE COMPANY THAT IT WAS NOT IN COMPLIANCE WITH NASDAQ'S CONTINUED LISTING REQUIREMENTS UNDER THE TIMELY FILING CRITERIA ESTABLISHED IN NASDAQ LISTING RULE 5250(C)(1).
|
YUNHONG INTERNATIONAL ANNOUNCES RECEIPT OF NOTICE FROM NASDAQ REGARDING LATE FILING OF ANNUAL REPORT ON FORM 10-K
|
ZGYH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-14 16:05:00
| null |
NEW YORK, NY / ACCESSWIRE / SEPTEMBER 14, 2021 / YUNHONG INTERNATIONAL (NASDAQ:ZGYH) (THE "COMPANY") TODAY ANNOUNCED THAT ON SEPTEMBER 8, 2021, THE COMPANY RECEIVED A WRITTEN NOTICE FROM GIGA CARBON NEUTRALITY INC. (F/K/A GIGA ENERGY INC.), A CORPORATION FORMED UNDER THE LAWS OF THE PROVINCE OF BRITISH COLUMBIA, CANADA ("GCN"), TERMINATING THE SHARE EXCHANGE AGREEMENT, DATED AS OF MAY 14, 2021 (THE "SHARE EXCHANGE AGREEMENT"), ENTERED INTO BY AND AMONG THE COMPANY, GCN AND THE OTHER PARTIES IDENTIFIED THEREIN, PURSUANT TO WHICH THE COMPANY AGREED TO PURCHASE FROM THE SHAREHOLDERS OF GCN ALL OF THE ISSUED AND OUTSTANDING SHARES OF GCN IN EXCHANGE FOR NEWLY ISSUED ORDINARY SHARES OF THE COMPANY, SUBJECT TO THE TERMS AND CONDITIONS SET FORTH IN THE SHARE EXCHANGE AGREEMENT (THE "BUSINESS COMBINATION"), BECAUSE THE BUSINESS COMBINATION HAD NOT BEEN CONSUMMATED BY JULY 30, 2021. ABOUT YUNHONG INTERNATIONAL YUNHONG INTERNATIONAL IS A BLANK CHECK COMPANY INCORPORATED AS A CAYMAN ISLANDS EXEMPTED COMPANY FOR THE PURPOSE OF EFFECTING A MERGER, SHARE EXCHANGE, ASSET ACQUISITION, SHARE PURCHASE, RECAPITALIZATION, REORGANIZATION OR SIMILAR BUSINESS COMBINATION WITH ONE OR MORE BUSINESSES OR ENTITIES.
|
YUNHONG INTERNATIONAL ANNOUNCES TERMINATION OF SHARE EXCHANGE AGREEMENT
|
ZGYH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-17 20:50:00
| null |
NEW YORK, NY / ACCESSWIRE / AUGUST 17, 2021 / YUNHONG INTERNATIONAL (NASDAQ:ZGYH) (THE "COMPANY" OR "YUNHONG") TODAY ANNOUNCED THAT AN AGGREGATE AMOUNT OF $690,000 HAS BEEN DEPOSITED INTO THE COMPANY'S TRUST ACCOUNT FOR ITS PUBLIC SHAREHOLDERS (THE "TRUST ACCOUNT"), REPRESENTING $0.10 PER PUBLIC SHARE, WHICH ENABLES THE COMPANY TO EXTEND THE PERIOD OF TIME IT HAS TO CONSUMMATE ITS INITIAL BUSINESS COMBINATION BY THREE MONTHS TO NOVEMBER 18, 2021. ON MAY 14, 2021, THE COMPANY EXECUTED A DEFINITIVE SHARE EXCHANGE AGREEMENT (THE "SHARE EXCHANGE AGREEMENT") WITH GIGA CARBON NEUTRALITY INC. (F/K/A GIGA ENERGY INC.) ("GCN"), A COMPANY THAT PLANS TO MARKET BOTH HYDROGEN FUEL CELL AND ADVANCED BATTERY INDUSTRIAL AND COMMERCIAL TRANSPORTATION PRODUCTS TO ADDRESS THE WORLD'S BIGGEST ENERGY CHALLENGES, THE SHAREHOLDERS OF GCN AND THE OTHER PARTIES IDENTIFIED THEREIN, PURSUANT TO WHICH THE COMPANY WILL PURCHASE FROM THE SHAREHOLDERS OF GCN ALL OF THE ISSUED AND OUTSTANDING SHARES AND ANY OTHER EQUITY INTERESTS IN OR OF GCN IN EXCHANGE FOR NEWLY ISSUED CLASS A ORDINARY SHARES OF THE COMPANY, SUBJECT TO THE TERMS AND CONDITIONS SET FORTH IN THE SHARE EXCHANGE AGREEMENT (THE "BUSINESS COMBINATION"), AFTER WHICH GCN WILL BECOME A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY AND THE COMPANY WILL RENAME ITSELF AS GIGA CARBON NEUTRALITY LTD.
|
YUNHONG INTERNATIONAL CONFIRMS FUNDING TO EXTEND PERIOD OF TIME TO CONSUMMATE INITIAL BUSINESS COMBINATION
|
ZGYH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-07-17 14:30:00
| null |
BOOTHBAY FUND MANAGEMENT LLC REPORTS 7.99% PASSIVE STAKE IN YUNHONG INTERNATIONAL AS OF JULY 13 - SEC FILING.
|
BOOTHBAY FUND MANAGEMENT LLC REPORTS 7.99% PASSIVE STAKE IN YUNHONG INTERNATIONAL
|
ZGYH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-05-29 08:30:00
| null |
HUDSON BAY CAPITAL MANAGEMENT LP REPORTS A PASSIVE STAKE OF 12.47% IN YUNHONG INTERNATIONAL AS OF FEB. 29 - SEC FILING.
|
HUDSON BAY CAPITAL MANAGEMENT REPORTS A PASSIVE STAKE OF 12.47% IN YUNHONG INTERNATIONAL AS OF FEB. 29
|
ZGYH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-02-13 15:30:00
| null |
:YUNHONG INTERNATIONAL UNITS OPEN AT $10.01 IN DEBUT ON NASDAQ VERSUS IPO PRICE OF $10.00 PER UNIT.
|
YUNHONG INTERNATIONAL UNITS OPEN 0.1% ABOVE IPO PRICE IN DEBUT ON NASDAQ
|
ZGYH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-30 08:19:00
| null |
BEIJING , JUNE 30, 2023 /PRNEWSWIRE/ -- ZHIHU INC. (NYSE: ZH; HKEX: 2390) ("ZHIHU" OR THE "COMPANY"), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED THAT EACH OF THE PROPOSED RESOLUTIONS SUBMITTED FOR SHAREHOLDERS' APPROVAL (THE "PROPOSED RESOLUTIONS") AS SET FORTH IN THE NOTICE OF ANNUAL GENERAL MEETING DATED JUNE 2, 2023 (THE "AGM NOTICE") HAS BEEN ADOPTED AT ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS HELD IN BEIJING, CHINA TODAY. AFTER THE ADOPTION OF THE PROPOSED RESOLUTIONS, ALL CORPORATE AUTHORIZATIONS AND ACTIONS CONTEMPLATED THEREUNDER ARE APPROVED, INCLUDING, AMONG OTHER THINGS, THAT (I) MR.
|
ZHIHU INC. ANNOUNCES RESULTS OF THE ANNUAL GENERAL MEETING
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-02 05:56:00
| null |
BEIJING , JUNE 2, 2023 /PRNEWSWIRE/ -- ZHIHU INC. (NYSE: ZH; HKEX: 2390) ("ZHIHU" OR THE "COMPANY"), A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED THAT IT WILL HOLD AN ANNUAL GENERAL MEETING OF THE COMPANY'S SHAREHOLDERS (THE "AGM") AT 10:00 A.M. BEIJING TIME ON JUNE 30, 2023 AT ROOM LANDING, FLOOR 1, ZONE B, CHINA INDUSTRY-ACADEMY-RESEARCH ACHIEVEMENT TRANSFORMATION CENTER, NO.
|
ZHIHU INC. TO HOLD ANNUAL GENERAL MEETING ON JUNE 30, 2023
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-24 06:21:00
| null |
BEIJING , MAY 24, 2023 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH; HKEX: 2390), A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED THAT THE COMPANY'S BOARD OF DIRECTORS (THE "BOARD") HAS APPROVED TO SPLIT THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE OF THE BOARD INTO A NOMINATION COMMITTEE (THE "NOMINATION COMMITTEE") AND A CORPORATE GOVERNANCE COMMITTEE (THE "CORPORATE GOVERNANCE COMMITTEE") WITH SEPARATE FUNCTIONS AND RESPONSIBILITIES UNDER SEPARATE CHARTERS. THE NOMINATION COMMITTEE WILL COMPRISE MR.
|
ZHIHU INC. ANNOUNCES CHANGES IN BOARD COMMITTEES
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-24 05:04:00
| null |
BEIJING , MAY 24, 2023 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH; HKEX: 2390), A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED ITS UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2023. FIRST QUARTER 2023 HIGHLIGHTS TOTAL REVENUES WERE RMB994.2 MILLION (US$144.8 MILLION) IN THE FIRST QUARTER OF 2023, REPRESENTING A 33.8% INCREASE FROM THE SAME PERIOD OF 2022.
|
ZHIHU INC. REPORTS UNAUDITED FIRST QUARTER 2023 FINANCIAL RESULTS
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-28 07:57:00
| null |
BEIJING , APRIL 28, 2023 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH; HKEX: 2390), A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED THAT IT FILED ITS ANNUAL REPORT ON FORM 20-F FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 28, 2023. THE ANNUAL REPORT CAN BE ACCESSED ON THE COMPANY'S INVESTOR RELATIONS WEBSITE AT HTTPS://IR.ZHIHU.COM.
|
ZHIHU INC. FILES ITS ANNUAL REPORT ON FORM 20-F
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-22 05:35:00
| null |
BEIJING , MARCH 22, 2023 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH; HKEX: 2390), A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED ITS UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND FISCAL YEAR ENDED DECEMBER 31, 2022. FOURTH QUARTER 2022 HIGHLIGHTS TOTAL REVENUES WERE RMB1,114.0 MILLION (US$161.5 MILLION) IN THE FOURTH QUARTER OF 2022, REPRESENTING A 9.3% INCREASE FROM THE SAME PERIOD OF 2021.
|
ZHIHU INC. REPORTS UNAUDITED FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-10 14:00:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - FEBRUARY 10, 2023) - SCOTT+SCOTT ATTORNEYS AT LAW LLP ("SCOTT+SCOTT"), AN INTERNATIONAL SHAREHOLDER AND CONSUMER RIGHTS LITIGATION FIRM, IS INVESTIGATING WHETHER ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH) AND/OR CERTAIN OF ITS OFFICERS AND DIRECTORS VIOLATED FEDERAL SECURITIES LAWS.
|
ONGOING INVESTIGATION REMINDER: SCOTT+SCOTT ATTORNEYS AT LAW LLP ANNOUNCES INVESTIGATION INTO ZHIHU INC. (ZH)
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-25 11:00:00
| null |
NEW YORK--( BUSINESS WIRE )--SCOTT+SCOTT ATTORNEYS AT LAW LLP (“SCOTT+SCOTT”), AN INTERNATIONAL SHAREHOLDER AND CONSUMER RIGHTS LITIGATION FIRM, IS INVESTIGATING WHETHER ZHIHU INC. (“ZHIHU” OR THE “COMPANY”) (NYSE: ZH) AND/OR CERTAIN OF ITS OFFICERS AND DIRECTORS VIOLATED FEDERAL SECURITIES LAWS. IF YOU PURCHASED ZHIHU AMERICAN DEPOSITORY SHARES (“ADS”) PURSUANT AND/OR TRACEABLE TO ZHIHU'S INITIAL PUBLIC OFFERING (“IPO”) IN MARCH 2021, YOU ARE ENCOURAGED TO CONTACT SCOTT+SCOTT ATTORNEY JONATHAN ZIMMERMAN AT (888) 398-9312 OR JZIMMERMAN@SCOTT-SCOTT.COM.
|
ONGOING INVESTIGATION ALERT: SCOTT+SCOTT ATTORNEYS AT LAW LLP ANNOUNCES INVESTIGATION INTO ZHIHU INC. (ZH)
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-20 11:00:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - JANUARY 20, 2023) - SCOTT+SCOTT ATTORNEYS AT LAW LLP ("SCOTT+SCOTT"), AN INTERNATIONAL SHAREHOLDER AND CONSUMER RIGHTS LITIGATION FIRM, IS INVESTIGATING WHETHER ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH) AND/OR CERTAIN OF ITS OFFICERS AND DIRECTORS VIOLATED FEDERAL SECURITIES LAWS.
|
INVESTIGATION NOTICE: SCOTT+SCOTT ATTORNEYS AT LAW LLP ANNOUNCES INVESTIGATION INTO ZHIHU INC. (ZH)
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-02 05:23:00
| null |
BEIJING , JAN. 2, 2023 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH; HKEX: 2390), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPOINTED MR. HENRY DACHUAN SHA AS A DIRECTOR AND THE CHIEF FINANCIAL OFFICER OF THE COMPANY, EFFECTIVE IMMEDIATELY.
|
ZHIHU INC. APPOINTS NEW DIRECTOR AND CHIEF FINANCIAL OFFICER
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-30 04:10:00
| null |
BEIJING , NOV. 30, 2022 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH; HKEX: 2390), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED ITS UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2022. THIRD QUARTER 2022 HIGHLIGHTS TOTAL REVENUES WERE RMB911.7 MILLION (US$128.2 MILLION) FOR THE THIRD QUARTER OF 2022, REPRESENTING A 10.7% INCREASE FROM THE SAME PERIOD OF 2021.
|
ZHIHU INC. REPORTS UNAUDITED THIRD QUARTER 2022 FINANCIAL RESULTS
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-28 14:46:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - OCTOBER 28, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZHIHU INC. ("ZHIHU" OR "THE COMPANY") (NYSE: ZH) FOR VIOLATIONS OF THE SECURITIES LAWS.THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.IF YOU ARE A SHAREHOLDER WHO SUFFERED A LOSS, CLICK HERE TO PARTICIPATE.
|
ONGOING INVESTIGATION ALERT: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN ZHIHU INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-26 16:30:00
| null |
LOS ANGELES, CA / ACCESSWIRE / OCTOBER 26, 2022 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZHIHU INC. ("ZHIHU" OR "THE COMPANY") (NYSE:ZH) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.
|
SHAREHOLDER ACTION NOTICE: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN ZHIHU INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-26 13:00:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 26, 2022) - SCOTT+SCOTT ATTORNEYS AT LAW LLP ("SCOTT+SCOTT"), AN INTERNATIONAL SHAREHOLDER AND CONSUMER RIGHTS LITIGATION FIRM, IS INVESTIGATING WHETHER ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH) AND CERTAIN MEMBERS OF ITS MANAGEMENT TEAM VIOLATED FEDERAL SECURITIES LAWS.CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONZHIHU, WHICH IS HEADQUARTERED IN BEIJING, CHINA, OPERATES AS AN ONLINE SHARE KNOWLEDGE COMMUNITY.
|
INVESTIGATION REMINDER: SCOTT+SCOTT ATTORNEYS AT LAW LLP ANNOUNCES INVESTIGATION INTO ZHIHU INC. (ZH)
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-19 09:30:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 19, 2022) - SCOTT+SCOTT ATTORNEYS AT LAW LLP ("SCOTT+SCOTT"), AN INTERNATIONAL SHAREHOLDER AND CONSUMER RIGHTS LITIGATION FIRM, IS INVESTIGATING WHETHER ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH) AND CERTAIN MEMBERS OF ITS MANAGEMENT TEAM VIOLATED FEDERAL SECURITIES LAWS.CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONZHIHU, WHICH IS HEADQUARTERED IN BEIJING, CHINA, OPERATES AS AN ONLINE SHARE KNOWLEDGE COMMUNITY.
|
INVESTIGATION ALERT: SCOTT+SCOTT ATTORNEYS AT LAW LLP ANNOUNCES INVESTIGATION INTO ZHIHU INC. (ZH)
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-05 09:12:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - OCTOBER 5, 2022) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZHIHU INC. ("ZHIHU" OR "THE COMPANY") (NYSE: ZH) FOR VIOLATIONS OF THE SECURITIES LAWS.THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.IF YOU ARE A SHAREHOLDER WHO SUFFERED A LOSS, CLICK HERE TO PARTICIPATE.
|
INVESTIGATION NOTICE: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN ZHIHU INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-04 11:00:00
| null |
LOS ANGELES--(BUSINESS WIRE)---- $ZH #ZH--THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN ZHIHU INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
INVESTIGATION REMINDER: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN ZHIHU INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-03 21:42:00
| null |
LOS ANGELES--(BUSINESS WIRE)---- $ZH #ZH--THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN ZHIHU INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
INVESTIGATION ALERT: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN ZHIHU INC. WITH LOSSES OF $100,000 TO CONTACT THE FIRM
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-30 06:31:00
| null |
BEIJING , AUG. 30, 2022 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH; HKEX: 2390), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED ITS UNAUDITED FINANCIAL RESULTS FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2022. SECOND QUARTER 2022 HIGHLIGHTS TOTAL REVENUES WERE RMB836.0 MILLION (US$124.8 MILLION) IN THE SECOND QUARTER OF 2022, REPRESENTING A GROWTH OF 31.0% OVER THE SECOND QUARTER OF 2021.
|
ZHIHU INC. REPORTS SECOND QUARTER AND FIRST HALF 2022 UNAUDITED FINANCIAL RESULTS
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-24 23:55:00
| null |
SHANGHAI , JULY 24, 2022 /PRNEWSWIRE/ -- QIMING VENTURE PARTNERS' PORTFOLIO COMPANY INVENTISBIO (SHSE: 688382), A LEADING COMPANY IN INNOVATIVE DRUG DEVELOPMENT, TODAY LISTED ON THE SCIENCE AND TECHNOLOGY INNOVATION BOARD (THE "STAR MARKET") OF THE SHANGHAI STOCK EXCHANGE. THE ISSUE PRICE IS CNY 18.12 PER SHARE, REPRESENTING A MARKET CAP OF CNY 10.419 BILLION.
|
QIMING'S PORTFOLIO COMPANY INVENTISBIO LISTS ON STAR MARKET
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-11 02:20:00
| null |
BEIJING , JUNE 11, 2022 /PRNEWSWIRE/ -- ZHIHU INC. (NYSE: ZH; HKEX: 2390) ("ZHIHU" OR THE "COMPANY"), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED THAT EACH OF THE PROPOSED RESOLUTIONS SUBMITTED FOR SHAREHOLDERS' APPROVAL (THE "PROPOSED RESOLUTIONS") AS SET FORTH IN THE NOTICE OF ANNUAL GENERAL MEETING DATED MAY 19, 2022 (THE "AGM NOTICE") HAS BEEN ADOPTED AT ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS, THE CLASS MEETING OF HOLDERS OF THE CLASS A ORDINARY SHARES WITH A PAR VALUE OF US$0.000125 EACH, AND THE CLASS MEETING OF HOLDERS OF CLASS B ORDINARY SHARES WITH A PAR VALUE OF US$0.000125 EACH HELD IN BEIJING, CHINA, ON JUNE 10, 2022. AFTER THE ADOPTION OF THE PROPOSED RESOLUTIONS, ALL CORPORATE AUTHORIZATIONS AND ACTIONS CONTEMPLATED THEREUNDER ARE APPROVED, INCLUDING, AMONG OTHER THINGS, THAT (I) THE COMPANY'S EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATIONS ARE AMENDED AND RESTATED BY THEIR DELETION IN THEIR ENTIRETY AND BY THE SUBSTITUTION IN THEIR PLACE OF THE ELEVENTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION AS SET OUT IN PART A OF APPENDIX I TO THE CIRCULAR OF THE COMPANY DATED MAY 19, 2022; (II) MR.
|
ZHIHU INC. ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING, CLASS A MEETING, AND CLASS B MEETING
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-25 06:12:00
| null |
BEIJING , MAY 25, 2022 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH; HKEX: 2390), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED ITS UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2022. FIRST QUARTER 2022 HIGHLIGHTS TOTAL REVENUES WERE RMB743.2 MILLION (US$117.2 MILLION) IN THE FIRST QUARTER OF 2022, REPRESENTING A GROWTH OF 55.4% OVER THE FIRST QUARTER OF 2021.
|
ZHIHU INC. REPORTS FIRST QUARTER 2022 UNAUDITED FINANCIAL RESULTS
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-18 18:30:00
| null |
BEIJING , MAY 18, 2022 /PRNEWSWIRE/ -- ZHIHU INC. (NYSE: ZH; HKEX: 2390) ("ZHIHU" OR THE "COMPANY"), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED THAT IT WILL HOLD AN ANNUAL GENERAL MEETING OF THE COMPANY'S SHAREHOLDERS (THE "AGM") AT 11:00 A.M. BEIJING TIME (OR SOON AFTER THE CLASS A MEETING AND THE CLASS B MEETING, BOTH OF WHICH ARE DEFINED BELOW) ON JUNE 10, 2022 AT ROOM XINZHI, GATE 10, BKL-B, 768 CREATIVE INDUSTRY PARK, 5A XUEYUAN ROAD, HAIDIAN DISTRICT, BEIJING, CHINA, FOR THE PURPOSES OF CONSIDERING AND, IF THOUGHT FIT, PASSING EACH OF THE PROPOSED RESOLUTIONS AS DEFINED AND SET FORTH IN THE NOTICE OF THE AGM (THE "AGM NOTICE").
|
ZHIHU INC. TO HOLD ANNUAL GENERAL MEETING ON JUNE 10, 2022
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-16 16:30:00
| null |
BEIJING , MAY 16, 2022 /PRNEWSWIRE/ -- ZHIHU INC. (NYSE: ZH; HKEX: 2390) ("ZHIHU" OR THE "COMPANY"), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED THE APPOINTMENT OF MR. DINGJIA CHEN AS A DIRECTOR OF THE COMPANY.
|
ZHIHU INC. ANNOUNCES BOARD CHANGES
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-14 09:27:00
| null |
BEIJING , APRIL 14, 2022 /PRNEWSWIRE/ -- ZHIHU INC. (NYSE: ZH) ("ZHIHU" OR THE "COMPANY"), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED THE PRICING OF THE GLOBAL OFFERING (THE "GLOBAL OFFERING") OF 26,000,000 CLASS A ORDINARY SHARES OF THE COMPANY (THE "SALE SHARES") BY CERTAIN SELLING SHAREHOLDERS, WHICH COMPRISES AN INTERNATIONAL OFFERING (THE "INTERNATIONAL OFFERING") AND A HONG KONG PUBLIC OFFERING (THE "HONG KONG PUBLIC OFFERING"). THE FINAL OFFERING PRICE FOR BOTH THE INTERNATIONAL OFFERING AND THE HONG KONG PUBLIC OFFERING (THE "OFFERING PRICE") HAS BEEN SET AS HK$32.06 PER SALE SHARE.
|
ZHIHU INC. ANNOUNCES PRICING OF GLOBAL OFFERING
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-08 16:56:00
| null |
BEIJING, APRIL 8, 2022 /PRNEWSWIRE/ -- ZHIHU INC. (NYSE: ZH) ("ZHIHU" OR THE "COMPANY"), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED THE LAUNCH OF ITS GLOBAL OFFERING (THE "GLOBAL OFFERING") OF 26,000,000 CLASS A ORDINARY SHARES OF THE COMPANY, WHICH COMPRISES A HONG KONG PUBLIC OFFERING OF INITIALLY 2,600,000 CLASS A ORDINARY SHARES COMMENCING ON APRIL 11, 2022, HONG KONG TIME (THE "HONG KONG PUBLIC OFFERING") AND AN INTERNATIONAL OFFERING OF INITIALLY 23,400,000 CLASS A ORDINARY SHARES COMMENCING TODAY (THE "INTERNATIONAL OFFERING"), AND DUAL-PRIMARY LISTING (THE "HONG KONG LISTING") OF ITS CLASS A ORDINARY SHARES ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "HONG KONG STOCK EXCHANGE") UNDER THE STOCK CODE "2390." THE COMPANY'S AMERICAN DEPOSITARY SHARES (THE "ADSS"), TWO OF WHICH REPRESENT ONE CLASS A ORDINARY SHARE OF THE COMPANY, WILL CONTINUE TO BE LISTED AND TRADED ON THE NEW YORK STOCK EXCHANGE ("NYSE").
|
ZHIHU INC. LAUNCHES GLOBAL OFFERING
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-08 08:16:00
| null |
BEIJING , APRIL 8, 2022 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED THAT IT FILED ITS ANNUAL REPORT ON FORM 20-F FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 8, 2022. THE ANNUAL REPORT CAN BE ACCESSED ON THE COMPANY'S INVESTOR RELATIONS WEBSITE AT HTTPS://IR.ZHIHU.COM/.
|
ZHIHU INC. FILES ITS ANNUAL REPORT ON FORM 20-F
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-14 06:00:00
| null |
BEIJING, MARCH 14, 2022 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED ITS UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND FISCAL YEAR ENDED DECEMBER 31, 2021. FOURTH QUARTER AND FULL YEAR 2021 HIGHLIGHTS AVERAGE MONTHLY ACTIVE USERS (MAUS)[1] REACHED 103.3 MILLION IN THE FOURTH QUARTER OF 2021, REPRESENTING A GROWTH OF 36.4% OVER THE FOURTH QUARTER OF 2020.
|
ZHIHU INC. REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 UNAUDITED FINANCIAL RESULTS
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-22 04:03:00
| null |
BEIJING, NOV. 22, 2021 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED ITS UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2021. THIRD QUARTER 2021 HIGHLIGHTS AVERAGE MONTHLY ACTIVE USERS (MAUS)[1] REACHED 101.2 MILLION IN THE THIRD QUARTER OF 2021, REPRESENTING A GROWTH OF 40.1% OVER THE THIRD QUARTER OF 2020.
|
ZHIHU INC. REPORTS THIRD QUARTER 2021 UNAUDITED FINANCIAL RESULTS
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-16 04:53:00
| null |
BEIJING, AUG. 16, 2021 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED ITS UNAUDITED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2021. SECOND QUARTER 2021 HIGHLIGHTS AVERAGE MONTHLY ACTIVE USERS (MAUS)[1] REACHED 94.3 MILLION IN THE SECOND QUARTER OF 2021, REPRESENTING A GROWTH OF 46.2% OVER THE SECOND QUARTER OF 2020.
|
ZHIHU INC. REPORTS SECOND QUARTER 2021 UNAUDITED FINANCIAL RESULTS
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-17 04:10:00
| null |
BEIJING, MAY 17, 2021 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH), THE OPERATOR OF ZHIHU, A LEADING ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED ITS UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2021. FIRST QUARTER 2021 HIGHLIGHTS AVERAGE MONTHLY ACTIVE USERS (MAUS) [1] REACHED 85.0 MILLION IN THE FIRST QUARTER OF 2021, REPRESENTING A GROWTH OF 37.7% OVER THE FIRST QUARTER OF 2020.
|
ZHIHU INC. REPORTS FIRST QUARTER 2021 UNAUDITED FINANCIAL RESULTS
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-26 22:13:00
| null |
SHANGHAI, MARCH 26, 2021 /PRNEWSWIRE/ -- QIMING VENTURE PARTNERS' PORTFOLIO COMPANY ZHIHU (NYSE: ZH) ON MARCH 26TH EST LISTED ON THE NEW YORK STOCK EXCHANGE. THE ISSUE PRICE IS US$9.5/ADS.
|
QIMING'S PORTFOLIO COMPANY ZHIHU LISTS ON NEW YORK STOCK EXCHANGE
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-26 08:30:00
| null |
BEIJING, MARCH 26, 2021 /PRNEWSWIRE/ -- ZHIHU INC. ("ZHIHU" OR THE "COMPANY") (NYSE: ZH), AN ICONIC ONLINE CONTENT COMMUNITY IN CHINA, TODAY ANNOUNCED THAT IT HAS PRICED ITS INITIAL PUBLIC OFFERING (THE "IPO") OF 55,000,000 AMERICAN DEPOSITARY SHARES ("ADSS"), AT US$9.5 PER ADS. THE AGGREGATE OFFERING SIZE OF THE IPO AND THE CONCURRENT PRIVATE PLACEMENTS DESCRIBED BELOW IS US$772.5 MILLION, ASSUMING THE UNDERWRITERS DO NOT EXERCISE THEIR OPTION TO PURCHASE ADDITIONAL ADSS, AND APPROXIMATELY US$850.9 MILLION, ASSUMING THE UNDERWRITERS EXERCISE THEIR OPTION TO PURCHASE ADDITIONAL ADSS IN FULL.
|
ZHIHU INC. ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
|
ZH
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-10 09:00:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)---- $ZI--ZOOMINFO LAUNCHED ITS FIRST INTEGRATED BRAND CAMPAIGN, ILLUSTRATING HOW ZOOMINFO HELPS BUSINESSES UNLOCK INSIGHTS, ENGAGE CUSTOMERS, AND WIN FASTER.
|
ZOOMINFO LAUNCHES BOLD NEW BRAND CAMPAIGN TARGETING GO-TO-MARKET PROFESSIONALS
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-29 09:00:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)--ZOOMINFO'S PARTNERSHIP WITH DATABRICKS DELIVERS ZOOMINFO'S COMPREHENSIVE B2B DATA DIRECTLY TO CUSTOMERS IN THE DATABRICKS MARKETPLACE.
|
ZOOMINFO PARTNERSHIP WITH DATABRICKS DELIVERS COMPREHENSIVE DATA DIRECTLY TO CUSTOMERS
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-05 09:00:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)--ZOOMINFO (NASDAQ: ZI), THE GO-TO-MARKET PLATFORM TO FIND, ACQUIRE, AND GROW CUSTOMERS, WILL PRESENT MULTIPLE CASE STUDIES FROM CUSTOMERS AND HOST THOUGHT LEADERSHIP SESSIONS AT THE FORRESTER B2B SUMMIT. THE FORRESTER B2B SUMMIT IS THE GO-TO EVENT THAT PROFESSIONALS TRUST TO DELIVER THE INFORMATION AND INSIGHT THEY NEED TO MAKE BOLDER, SMARTER DECISIONS AND IS BEING HELD IN-PERSON JUNE 5–7 IN AUSTIN, TEXAS AS WELL AS VIRTUALLY. ZOOMINFO WILL SHARE ITS EXPERTISE.
|
ZOOMINFO TO SPEAK AT FORRESTER B2B SUMMIT IN AUSTIN
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-31 09:04:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)---- $ZI--ZOOMINFO HAS RELEASED NEW AND ENHANCED PRODUCT FEATURES TO HELP BUSINESSES UNLOCK INSIGHTS, ENGAGE CUSTOMERS, AND WIN FASTER.
|
ZOOMINFO DELIVERS PRODUCT ENHANCEMENTS POWERED BY GENERATIVE AI AND AUTOMATION
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-11 09:00:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)--ZOOMINFO, THE GO-TO-MARKET PLATFORM TO FIND, ACQUIRE, AND GROW CUSTOMERS, WAS RECOGNIZED BY TRUSTRADIUS WITH SEVEN TOP RATED AWARDS.
|
ZOOMINFO WINS SEVEN TRUSTRADIUS TOP RATED AWARDS, INCLUDING INTENT DATA, SALES INTELLIGENCE, AND CONVERSATION INTELLIGENCE
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-06 09:00:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)--ZOOMINFO CHIEF COMPLIANCE OFFICER SIMON MCDOUGALL HAS BEEN APPOINTED TO THE BOARD OF THE INTERNATIONAL ASSOCIATION OF PRIVACY PROFESSIONALS (IAPP).
|
ZOOMINFO CHIEF COMPLIANCE OFFICER SIMON MCDOUGALL APPOINTED TO BOARD OF INTERNATIONAL ASSOCIATION OF PRIVACY PROFESSIONALS
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-14 06:00:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)--ZOOMINFO (NASDAQ: ZI) (THE “COMPANY”), THE GO-TO-MARKET PLATFORM TO FIND, ACQUIRE, AND GROW CUSTOMERS, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS APPROVED A SHARE REPURCHASE PROGRAM AUTHORIZING THE COMPANY TO REPURCHASE, FROM TIME TO TIME, UP TO $100 MILLION OF THE COMPANY'S COMMON STOCK.
|
ZOOMINFO ANNOUNCES $100 MILLION SHARE REPURCHASE PROGRAM
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-17 09:00:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)---- $ZI--ZOOMINFO TODAY RELEASED ITS 2022 SUSTAINABILITY REPORT.
|
ZOOMINFO PUBLISHES 2022 SUSTAINABILITY REPORT
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-06 16:05:00
| null |
BUSINESS WIRE BODY {FONT: NORMAL SMALL ARIAL,HELVETICA,SANS-SERIF} H1 {FONT-SIZE:175%;COLOR:#00659C;} H2 {FONT-SIZE:130%;COLOR:#00659C;BORDER-TOP:1PX SOLID #CCC;PADDING-TOP:25PX;} A:LINK {COLOR: #005582;} A:VISITED {COLOR: #004469;} A:ACTIVE, A:HOVER {COLOR: #EE551C;} A IMG {BORDER:0;} .EPI-PAGEBG {BACKGROUND-COLOR:#FFF;} DIV {PADDING:12PX 0;WIDTH:50%;} DIV.ERROR-BODY {MAX-WIDTH:60EM;WIDTH:AUTO;MARGIN:80PX AUTO;FONT-SIZE:16PX;} DIV H1, DIV H2, DIV P, DIV DIV {MARGIN-RIGHT:12PX;MARGIN-LEFT:12PX;} DIV UL {MARGIN-LEFT:12PX;PADDING-LEFT:2EM;} DIV UL LI {MARGIN-BOTTOM:5PX;} DIV#BANNER {BORDER-BOTTOM:1PX SOLID #CCC;FLOAT:NONE;WIDTH:100%;} DIV#BANNER A IMG,DIV#BANNER A SVG {MARGIN:0 20PX;} BUSINESS WIRE'S WEBSITE IS CURRENTLY UNAVAILABLE WE APOLOGIZE FOR THE INCONVENIENCE. OUR TEAM IS WORKING TO RESOLVE THE ISSUE. IF YOU HAVE QUESTIONS OR NEED TO SUBMIT A NEWS RELEASE, PLEASE CONTACT YOUR LOCAL BUSINESS WIRE BUREAU: US: +1.888.381.WIRE(9473) AUSTRALIA: +61 2.9004.7015 CANADA: +1.416.593.0208 FRANCE: +33 1.56.88.29.40 GERMANY: +49 69.915066.0 HONG KONG: +852.3602.3091 JAPAN: +81 3.3239.0755 UK: +44 20.7626.1982 DOCUMENT.GETELEMENTBYID('IMAGELOGO').INNERHTML = ' '; (FUNCTION(){VAR F5_CSPM={F5_P:'GPLNKGGAEGIBHIENMFFNMHDGFIEDMPIOBKFGFBHPFGFHNKMHALCCNFAJFFBJMIFKNHLBNNEPAABMCLJFDLJACLDMAAANOIMPBDMMGGCFHILFDHJEOEMEBAIBHMJEFPBF',SETCHARAT:FUNCTION(STR,INDEX,CHR){IF(INDEX>STR.LENGTH-1)RETURN STR;RETURN STR.SUBSTR(0,INDEX)+CHR+STR.SUBSTR(INDEX+1);},GET_BYTE:FUNCTION(STR,I){VAR S=(I/16)|0;I=(I&15);S=S*32;RETURN((STR.CHARCODEAT(I+16+S)-65)4)+65));STR=F5_CSPM.SETCHARAT(STR,(I+S),STRING.FROMCHARCODE((B&15)+65));RETURN STR;},SET_LATENCY:FUNCTION(STR,LATENCY){LATENCY=LATENCY&0XFFFF;STR=F5_CSPM.SET_BYTE(STR,40,(LATENCY>>8));STR=F5_CSPM.SET_BYTE(STR,41,(LATENCY&0XFF));STR=F5_CSPM.SET_BYTE(STR,35,2);RETURN STR;},WAIT_PERF_DATA:FUNCTION(){TRY{VAR WP=WINDOW.PERFORMANCE.TIMING;IF(WP.LOADEVENTEND>0){VAR RES=WP.LOADEVENTEND-WP.NAVIGATIONSTART;IF(RES
|
ZOOMINFO ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-04 09:00:00
| null |
VANCOUVER, WASH.--( BUSINESS WIRE )--ZOOMINFO (NASDAQ: ZI), A GLOBAL LEADER IN MODERN GO-TO-MARKET SOFTWARE, DATA, AND INTELLIGENCE, TODAY ANNOUNCED THAT ITS EMPLOYEES RAISED MORE THAN $400,000 DURING ITS 2022 WINTER DONATION DRIVE TO SUPPORT YOUTH- AND FAMILY-FOCUSED NONPROFIT ORGANIZATIONS IN THEIR COMMUNITIES.
|
ZOOMINFO EMPLOYEES RAISE MORE THAN $400,000 FOR YOUTH AND FAMILY NONPROFITS DURING 2022 WINTER DONATION DRIVE
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-22 09:00:00
| null |
VANCOUVER, WASH.--( BUSINESS WIRE )--ZOOMINFO (NASDAQ: ZI), A GLOBAL LEADER IN MODERN GO-TO-MARKET SOFTWARE, DATA, AND INTELLIGENCE, HAS EARNED 29 NO. 1 RANKINGS ACROSS 87 GRIDS IN THE G2 WINTER 2023 GRID® REPORTS, SETTING A COMPANY RECORD FOR TOP RANKINGS AND EXPANDING ITS LEADERSHIP IN ENTERPRISE CATEGORIES.
|
ZOOMINFO SETS COMPANY RECORD WITH 29 TOP PRODUCT RATINGS ON G2 WINTER GRIDS
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-29 09:00:00
| null |
VANCOUVER, WASH.--( BUSINESS WIRE )--ZOOMINFO (NASDAQ: ZI), A GLOBAL LEADER IN MODERN GO-TO-MARKET SOFTWARE, DATA, AND INTELLIGENCE, TODAY ANNOUNCED ITS SALESOS SOLUTION HAS BEEN NAMED TO THE FIRST-EVER BEST SOFTWARE LIST BY TRUSTED RESEARCH AND REVIEW PLATFORM TRUSTRADIUS. THE LIST RANKS THE BEST SOFTWARE PRODUCTS BASED ON CUSTOMER SATISFACTION, REVIEW PERFORMANCE, AND MARKET-SIZE FIT. ZOOMINFO WAS ALSO HONORED ON THEIR BEST ENTERPRISE, MID-MARKET, AND SMALL BUSINESS LISTS.
|
ZOOMINFO WINS FOUR TRUSTRADIUS BEST SOFTWARE AWARDS
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-27 09:00:00
| null |
VANCOUVER, WASH.
|
ZOOMINFO RENEWS TRUSTE ENTERPRISE PRIVACY CERTIFICATION AND JOINS SECURITY SHARING NONPROFIT SAFECODE
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-04 09:00:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)---- $ZI--ZOOMINFO ANNOUNCED THAT ITS GLOBAL CONTACT DATABASE HAS GROWN TO MORE THAN 235 MILLION BUSINESS-TO-BUSINESS (B2B) PROFESSIONAL PROFILES.
|
ZOOMINFO GROWS GLOBAL BUSINESS CONTACTS TO MORE THAN 235 MILLION
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-30 09:00:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)--ZOOMINFO NOW DELIVERS INSIGHTS INTO THE TECHNOLOGY SOLUTIONS USED BY 30 MILLION COMPANIES, ALLOWING CUSTOMERS TO ACCURATELY TARGET THEIR CAMPAIGNS.
|
ZOOMINFO PROVIDES TECHNOLOGY USAGE INSIGHTS FOR MORE THAN 30 MILLION COMPANIES
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-01 16:05:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)--ZOOMINFO, (NASDAQ: ZI) A GLOBAL LEADER IN MODERN GO-TO-MARKET SOFTWARE, DATA, AND INTELLIGENCE, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2022. “CUSTOMERS OF ALL SIZES AND INDUSTRIES ARE LEVERAGING ZOOMINFO DATA, INSIGHTS, AUTOMATION, AND WORKFLOWS TO DRIVE A MORE EFFICIENT GO-TO-MARKET MOTION, WHICH IS CRITICAL IN ANY ECONOMIC ENVIRONMENT,” SAID HENRY SCHUCK, ZOOMINFO FOUNDER AND CEO. “OUR PLATFORM STRATEGY IS RESONATING WITH
|
ZOOMINFO ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-26 09:00:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)---- $ZI--ZOOMINFO ANNOUNCED THE APPOINTMENT OF TOMER GERSHONI AS ITS CHIEF SECURITY OFFICER.
|
ZOOMINFO APPOINTS TOMER GERSHONI AS FIRST CHIEF SECURITY OFFICER
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-20 09:00:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)--ZOOMINFO HAS HIRED CHAD HERRING AS CHIEF HUMAN RESOURCES OFFICER. HE BRINGS EXPERIENCE OVERSEEING PEOPLE OPERATIONS FOR MULTIPLE PUBLIC COMPANIES.
|
ZOOMINFO NAMES CHAD HERRING CHIEF HUMAN RESOURCES OFFICER
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-05 09:00:00
| null |
VANCOUVER, WASH.--(BUSINESS WIRE)---- $ZI--ZOOMINFO ANNOUNCED A STRATEGIC PARTNERSHIP WITH SALES CONFIDENCE.
|
ZOOMINFO PARTNERS WITH SALES CONFIDENCE TO EMPOWER REVENUE PROFESSIONALS THROUGH SALES SOLUTIONS AND DATA PRIVACY COMPLIANCE
|
ZI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.